Page 1

Endo International PLC completes acquisition of DAVA Pharmaceuticals

Wednesday, 6 Aug 2014 05:00pm EDT

Endo International PLC:Completes acquisition of DAVA Pharmaceuticals, Inc., privately-held company specializing in generic pharmaceuticals, with portfolio of marketed, pre-launch and pipeline products, for $575 mln in cash.Also additional cash consideration of up to $25 mln contingent on achievement of certain sales milestones.DAVA portfolio is well-positioned for continued strong financial performance with existing commercial products and attractive near-term pipeline, and is natural fit with Endo's U.S. generics business.

AbbVie Inc and Shire Plc reach agreement on terms of recommended combination

Friday, 18 Jul 2014 05:00am EDT

AbbVie Inc and Shire Plc:Says they have reached agreement on the terms of a recommended combination of Shire with AbbVie.Under the terms of the Merger, Shire shareholders will be entitled to receive: for each Shire Share: 24.44 Pounds in cash and 0.8960 New AbbVie Shares.Immediately following the Transaction, Shire shareholders are expected to hold New AbbVie Shares representing about 25 pct of the issued share capital of New AbbVie, thus offering Shire Shareholders the ability to participate in the future prospects of the Combined Group.AbbVie Stockholders are expected to hold New AbbVie Shares representing about 75 pct of the issued share capital of New AbbVie.AbbVie Board has approved the Transaction and intends to recommend that AbbVie Stockholders vote in favour of the adoption of the US Merger Agreement.In order to undertake the transaction, AbbVie has formed a new company, New AbbVie, which is incorporated in Jersey, Shire's current place of incorporation.Following completion of the transaction, New AbbVie will become the holding company of the Shire Group and the AbbVie Group.

AbbVie Inc and Shire Plc reach agreement on terms of recommended combination

Friday, 18 Jul 2014 05:00am EDT

AbbVie Inc and Shire Plc:Says they have reached agreement on the terms of a recommended combination of Shire with AbbVie.Under the terms of the Merger, Shire shareholders will be entitled to receive: for each Shire Share: 24.44 Pounds in cash and 0.8960 New AbbVie Shares.Immediately following the Transaction, Shire shareholders are expected to hold New AbbVie Shares representing about 25 pct of the issued share capital of New AbbVie, thus offering Shire Shareholders the ability to participate in the future prospects of the Combined Group.AbbVie Stockholders are expected to hold New AbbVie Shares representing about 75 pct of the issued share capital of New AbbVie.AbbVie Board has approved the Transaction and intends to recommend that AbbVie Stockholders vote in favour of the adoption of the US Merger Agreement.In order to undertake the transaction, AbbVie has formed a new company, New AbbVie, which is incorporated in Jersey, Shire's current place of incorporation.Following completion of the transaction, New AbbVie will become the holding company of the Shire Group and the AbbVie Group.

Cipla Ltd's MSPL acquires Mabpharm

Thursday, 17 Jul 2014 06:57am EDT

Cipla Ltd:Says a subsidiary Meditab Specialities Pvt Ltd (MSPL), has acquired 75 pct stake in Mabpharm Pvt Ltd(Mabpharm).The company was earlier holding 25 pct stake in Mabpharm.Consequent to the acquisition of the aforesaid stake, Mabpharm has now become 100 pct subsidiary of the company.Mabpharm is inter alia engaged in development of monoclonal anitbodies for treatment of cancer and auto-immune diseases.Financial terms of the acquisition were not disclosed.

Pfizer Inc to acquire InnoPharma, Inc

Wednesday, 16 Jul 2014 09:26am EDT

Pfizer Inc:InnoPharma, Inc and Pfizer Inc entered into an agreement under which Pfizer will acquire InnoPharma.Under terms of agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 mln, with up to $135 mln of contingent milestone payments.

Sun Pharmaceutical Industries Ltd's subsidiary acquires Pharmalucence Inc

Tuesday, 15 Jul 2014 11:34pm EDT

Sun Pharmaceutical Industries Ltd:Announces acquisition of Pharmalucence Inc, by one of its subsidiaries.Pharmalucence has sterile injectable capacity in the US, supported by R&D capabilities.Terms of the acquisition were not disclosed.

Hikma Pharmaceuticals PLC completes acquisition of assets

Tuesday, 15 Jul 2014 10:35am EDT

Hikma Pharmaceuticals PLC:Completes acquisition of assets of US generic injectables business, Bedford Laboratories (Bedford) from Ben Venue Laboratories, Inc., member of Boehringer Ingelheim Group of Companies.As previously announced, total consideration of up to $300 mln will be satisfied through an upfront cash payment of $225 mln.Contingent cash payments of up to $75 mln, subject to achievement of performance-related milestones over a period of five years.

Chi Sheng Chemical Corp to invest in subsidiary

Tuesday, 15 Jul 2014 04:48am EDT

Chi Sheng Chemical Corp:To invest $7 million to buy 7 million shares of subsidiary G SHENG INTERNATIONAL LIMITED at a price of $1 per share.To hold 1.502 million shares (100 pct stake) of G SHENG INTERNATIONAL LIMITED.

Anthera Pharmaceuticals announces acquisition of Sollpura

Monday, 14 Jul 2014 04:42pm EDT

Anthera Pharmaceuticals Inc:Announces that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases.

Mylan Inc to acquire Abbott's non-U.S. developed markets specialty and branded generics business

Monday, 14 Jul 2014 06:30am EDT

Mylan Inc:Has entered into a definitive agreement with Abbott Laboratories whereby Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business in an all-stock transaction.Upon closing, Abbott will receive 105 million shares of the combined company worth about $5.3 billion based on Mylan's closing price of $50.20 on July 11, representing an about 21 pct ownership stake.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.